Loading…
Loading…
VRTX · NASDAQ · Healthcare
“At nearly 29 times earnings, Vertex's valuation demands exceptional scrutiny of its drug pipeline durability to justify such a premium over conservative investment principles.”
— In the voice of Graham
Estimate fair value using the Graham Number, earnings-based model, and PEG-adjusted valuation. Three independent methods averaged together.
Market Cap
$114.58B
P/E Ratio
28.98
Forward P/E
—
EPS
$15.46
PEG Ratio
0.88
Book Value
$73.00
Dividend Yield
—
Profit Margin
32.94%
ROE
21.18%
Use the interactive fair value with pre-loaded data for Vertex Pharmaceuticals Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for VRTX: